Clinical Trial Update: A Randomised, Double- Blind, Placebo Controlled, Cross-over Efficacy and Safety Comparison of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for Four Weeks in Patients With Moderate Persistent Asthma [Phase 2]

View source ↗

Summary

Phase 2 randomized, double-blind, placebo-controlled cross-over study comparing tiotropium 5 µg once daily with 2.5 µg twice daily for four weeks in adults with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Spiriva (tiotropium)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Asthma | Phase 2 | Status: COMPLETED | Results posted: 2012-10-30